Online gift

Multiple sclerosis - Live from the research front - April 2025

Each scientific advance in the fight against multiple sclerosis means further hope for patients and their families. The recent designation by the FDD of tolebrutinib as a “breakthrough therapy” for multiple sclerosis is a new source of hope for the secondary progressive forms of the disease. By targeting both innate and adaptive immunity, this treatment opens up new therapeutic possibilities and may well transform patient care in the future.

The understanding and control of the immune cells responsible for brain lesions is a key issue. Researchers are currently working on strategies to modulate inflammation and encourage myelin repair. These developing leads remind us that research is a lengthy process in which each discovery is a milestone on the way to a better future. May we thank Professor Jérôme Hendriks for his valuable presentation of these mechanisms and of potential future therapies.

That same spirit of perseverance and commitment is also to be found in the people who actively support research. Soon, dozens of runners will be taking part in the Brussels 20-km race and uniting their endeavours to advance science. You can encourage them by cheering them on, or contribute to their endeavour by sponsoring them. Every little counts and brings us closer to new victories against multiple sclerosis.

Finally, I would like to express my deep gratitude to the researchers whose hard work and determination have enabled such breakthroughs. We owe them the hope of an MS-free future, which is drawing closer each day.

Happy reading and thank you for your faithful support!

Prof. Dr Christian Sindic

The references of all the studies cited are available on request from the Belgian Charcot Foundation: info@fondation-charcot.org
© Fondation Charcot Stichting - 2025